Insider Selling: Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Sells $31,667.22 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 9,022 shares of the business’s stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $3.51, for a total transaction of $31,667.22. Following the completion of the sale, the insider directly owned 81,385 shares of the company’s stock, valued at $285,661.35. The trade was a 9.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Thursday, July 2nd, Financial Lp Hrt acquired 7,851 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.54 per share, with a total value of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt purchased 3,959 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.23 per share, with a total value of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt bought 25,836 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.44 per share, for a total transaction of $88,875.84.

Shuttle Pharmaceuticals Stock Performance

Shares of Shuttle Pharmaceuticals stock traded down $0.24 during trading on Tuesday, hitting $3.26. 109,982 shares of the stock were exchanged, compared to its average volume of 543,961. The stock has a market cap of $2.08 million, a PE ratio of -0.07 and a beta of 0.29. The stock’s fifty day moving average is $5.57 and its 200 day moving average is $10.46. Shuttle Pharmaceuticals Holdings, Inc. has a 12 month low of $2.90 and a 12 month high of $55.90.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a research note on Saturday. Weiss Ratings raised Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Shuttle Pharmaceuticals has an average rating of “Sell”.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Ikarian Capital LLC bought a new stake in shares of Shuttle Pharmaceuticals during the 4th quarter worth $124,000. Connective Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals in the 3rd quarter valued at approximately $357,000. Boothbay Fund Management LLC acquired a new position in shares of Shuttle Pharmaceuticals during the fourth quarter worth approximately $37,000. Finally, Geode Capital Management LLC bought a new stake in Shuttle Pharmaceuticals in the 4th quarter valued at $26,000. Institutional investors and hedge funds own 4.58% of the company’s stock.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .